| AMPK | Adenosine Monophosphate Activated Protein Kinase; |
| BMI | Body Mass Index; |
| CV | Coefficient of Variation; |
| CI | Confidence Intervals; |
| C16:1 | Hexadecenoylcarnitine; |
| C14 | Tetradecanoylcarnitine; |
| C12 | Dodecanoylcarnitine; |
| C5-OH | Hydroxyvalerylcarnitine; |
| C16:2-OH | Hydroxyhexadecadienylcarnitine; |
| C3:1 | Propenoylcarnitine; |
| C2 | Acetylcarnitine; |
| CPT | Carnitine Palmitoyl-transferase; |
| CACT | Carnitine-acylcarnitine Translocase; |
| CAT | Carnitine Acyltransferase; |
| CoA | Coenzyme A; |
| lysoPC 18:2 | Lysophosphatidylcholine 18:2; |
| LOD | Limit of Detection; |
| LC/MC | Long-chain/Medium-chain; |
| MRI | Magnetic Resonance Imaging; |
| NHANES III | The Third National Health and Nutrition Examination Survey; |
| OA | Osteoarthritis; |
| PC 44:3 | Phosphatidylcholine 44:3; |
| PCA | Principal component analysis; |
| QC | Quality Control; |
| RA | Rheumatoid Arthritis; |
| TASOAC | Tasmania Older Adult Cohort; |
| TMIC | The Metabolomics Innovation Centre; |
| UHPLC | Ultra-high-performance Liquid Chromatography. |